Mutual of America Capital Management LLC Sells 19,396 Shares of Insmed Incorporated (NASDAQ:INSM)

Mutual of America Capital Management LLC decreased its holdings in Insmed Incorporated (NASDAQ:INSM) by 20.1% during the 4th quarter, HoldingsChannel reports. The firm owned 76,928 shares of the biopharmaceutical company’s stock after selling 19,396 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Insmed were worth $2,384,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Assetmark Inc. grew its position in Insmed by 10.7% during the 3rd quarter. Assetmark Inc. now owns 4,799 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 463 shares during the last quarter. Arizona State Retirement System grew its position in Insmed by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 38,846 shares of the biopharmaceutical company’s stock worth $981,000 after acquiring an additional 526 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Insmed by 12.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 5,579 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 604 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Insmed during the 4th quarter worth $25,000. Finally, Diversified Trust Co grew its position in Insmed by 4.2% during the 3rd quarter. Diversified Trust Co now owns 19,634 shares of the biopharmaceutical company’s stock worth $496,000 after acquiring an additional 792 shares during the last quarter.

Insmed Price Performance

Shares of Insmed stock opened at $24.32 on Friday. Insmed Incorporated has a one year low of $17.41 and a one year high of $32.00. The firm has a market capitalization of $3.61 billion, a price-to-earnings ratio of -4.55 and a beta of 0.92. The business has a 50-day simple moving average of $27.45 and a 200 day simple moving average of $27.02.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The company had revenue of $83.70 million during the quarter, compared to analyst estimates of $82.15 million. During the same period last year, the firm earned ($1.20) earnings per share. Insmed’s quarterly revenue was up 41.1% compared to the same quarter last year. On average, sell-side analysts expect that Insmed Incorporated will post -4.65 EPS for the current year.

Wall Street Analyst Weigh In

INSM has been the topic of a number of research reports. Wolfe Research initiated coverage on Insmed in a research report on Thursday, February 15th. They set an “outperform” rating and a $42.00 price objective on the stock. Guggenheim lifted their target price on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. UBS Group initiated coverage on Insmed in a report on Tuesday, February 27th. They set a “buy” rating and a $46.00 target price on the stock. StockNews.com raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $55.00 target price on shares of Insmed in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.64.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.